Abstract:Background Novel adjuvant strategies are needed to optimise outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). We aimed to evaluate adjuvant atezolizumab versus best supportive care after adjuvant platinum-based chemotherapy in these patients. Methods IMpower010 was a randomised, multicentre, open-label, phase 3 study done at 227 sites in 22 countries and regions. Eligible patients were 18 years or older with completely resected stage IB (tumours >= 4 cm) to IIIA NSCLC per the Union Internationale Contre le Cancer and American Joint Committee on Cancer staging system (7th edition). Patients were randomly assigned (1:1) by a permuted-block method (block size of four) to receive adjuvant atezolizumab (1200 mg every 21 days; for 16 cycles or 1 year) or best supportive care (observation and regular scans for disease recurrence) after adjuvant platinum-based chemotherapy (one to four cycles). The primary endpoint, investigator-assessed disease-free survival, was tested hierarchically first in the stage II-IIIA population subgroup whose tumours expressed PD-L1 on 1% or more of tumour cells (SP263), then all patients in the stage II-IIIA population, and finally the intention-to-treat (ITT) population (stage IB-IIIA). Safety was evaluated in all patients who were randomly assigned and received atezolizumab or best supportive care. IMpower010 is registered with ClinicalTrials.gov, NCT02486718 (active, not recruiting). Findings Between Oct 7, 2015, and Sept 19, 2018, 1280 patients were enrolled after complete resection. 1269 received adjuvant chemotherapy, of whom 1005 patients were eligible for randomisation to atezolizumab (n=507) or best supportive care (n=498); 495 in each group received treatment. After a median follow-up of 32.2 months (IQR 27.4-38.3) in the stage II-IIIA population, atezolizumab treatment improved disease-free survival compared with best supportive care in patients in the stage II-IIIA population whose tumours expressed PD-L1 on 1% or more of tumour cells (HR 0.66; 95% CI 0.50-0.88; p=0.0039) and in all patients in the stage II-IIIA population (0.79; 0.64-0.96; p=0.020). In the ITT population, HR for disease-free survival was 0.81 (0.67-0.99; p=0.040). Atezolizumab-related grade 3 and 4 adverse events occurred in 53 (11%) of 495 patients and grade 5 events in four patients (1%). Interpretation IMpower010 showed a disease-free survival benefit with atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected stage II-IIIA NSCLC, with pronounced benefit in the subgroup whose tumours expressed PD-L1 on 1% or more of tumour cells, and no new safety signals. Atezolizumab after adjuvant chemotherapy offers a promising treatment option for patients with resected early-stage NSCLC. Copyright (C) 2021 Elsevier Ltd. All rights reserved.

P48.02 NRG Oncology/Alliance LU005: Chemoradiation Vs. Chemoradiation Plus Atezolizumab in Limited Stage Small Cell Lung Cancer

NRG Oncology/Alliance LU005: A phase II/III randomized clinical trial of chemoradiation versus chemoradiation plus atezolizumab in limited stage small cell lung cancer.

PS01.55: IMpower010: Phase III Study of Atezolizumab Vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC: Topic: Medical Oncology.

P3.02c-050 IMpower010: Phase III Study of Atezolizumab Vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC

A Phase III Trial to Compare Atezolizumab (atezo) Vs Best Supportive Care (BSC) Following Adjuvant Chemotherapy in Patients (pts) with Completely Resected NSCLC: IMpower010.

Pembrolizumab Plus Chemotherapy for Chinese Patients with Metastatic Squamous NSCLC in KEYNOTE-407

Adjuvant Atezolizumab after Adjuvant Chemotherapy in Resected Stage IB–IIIA Non-Small-cell Lung Cancer (impower010): a Randomised, Multicentre, Open-Label, Phase 3 Trial

Long-term Survival Follow-Up of Atezolizumab in Combination with Platinum-Based Doublet Chemotherapy in Patients with Advanced Non-Small-cell Lung Cancer

First-line Atezolizumab/durvalumab Plus Platinum–etoposide Combined with Radiotherapy in Extensive-Stage Small-Cell Lung Cancer

Recent developments in limited stage small cell lung cancer

Real Clinical Practice of Combined Atezolizumab Plus Chemotherapy in Patients With Small Cell Lung Cancer

EP14.01-021 Anlotinib Plus Irinotecan or Docetaxel in Small-Cell Lung Cancer (SCLC) Relapsed Within Six Months: a Single-Arm Phase II Study

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).

P2.16-01 Sintilimab in Combination with Carboplatin/Cisplatin and Etoposide in the Treatment of Patients with Previously Untreated ES-SCLC

P48.09 Anlotinib Plus Etoposide and Carboplatin As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: A Single Arm Phase II Trial

A Phase II Prospective Study of Definitive Thoracic Concurrent Chemoradiation Followed by Consolidation Chemotherapy for Oligometastatic Non-Small Cell Lung Cancer.

A Phase II Exploratory Trial of Adebrelimab in Combination with Chemotherapy and Concurrent Radiotherapy As a First-Line Treatment for Oligo-Metastatic Extensive-Stage Small-Cell Lung Cancer.

A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic NSCLC

Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial

Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer

Neoadjuvant attelizumab combined chemotherapy in limited-stage and resectable small cell lung cancer: A multicentric, single-arm and open study.